Lupin launches generic Femhrt tablets in US
New Delhi : Drug firm Lupin has launched its generic norethindrone acetate and ethinyl estradiol tablets used for the prevention of postmenopausal osteoporosis in the US market.
The company's US subsidiary Lupin Pharmaceuticals Inc has launched FyavolvTM tablets (Norethindrone Acetate and Ethinyl Estradiol tablets USP, 0.5 mg/0.0025 mg and 1 mg/0.005 mg), in the American market, Lupin said in a BSE filing.
The company had earlier received an approval from the United States Food and Drug Administration (USFDA) to market the product, it added.
The product is generic version of Warner Chilcott's Femhrt tablets in the same strengths, Lupin said.
Femhrt had US sales of USD 39 million (IMS MAT December 2015), it added.
The tablets are indicated for the treatment of moderate to severe vasomotor symptoms due to menopause and prevention of postmenopausal osteoporosis, Lupin said.
Stock of Lupin closed 1.65 per cent higher at Rs 1,569.30 on BSE.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd